United Therapeutics Sells Priority Review Voucher to AbbVie

21.08.2015 - US biotechnology company United Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Boucher (PPRV) to a subsidiary of biopharmaceutical firm AbbVie for $350...